Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 8/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275491 | 0.93 | MAPKAPK5 (0.43) | MAPKAPK5ERN1PIM1TTKFLT3 | |
| SCHEMBL274671 | 0.92 | MAPKAPK5 (0.42) | MAPKAPK5TTKFLT3 | |
| SCHEMBL274498 | 0.92 | MAPKAPK5 (0.42) | MAPKAPK5FYNMKNK1TTKMAPK1 | |
| SCHEMBL275869 | 0.92 | MAPKAPK5 (0.42) | MAPKAPK5MKNK1TTKCD38MAPK1 | |
| SCHEMBL273763 | 0.91 | MAPKAPK5 (0.41) | MAPKAPK5FYNMKNK1TTKCD38 | |
| SCHEMBL275197 | 0.89 | MAPKAPK5 (0.40) | MAPKAPK5FYNPIM1TTKCD38 | |
| SCHEMBL273772 | 0.83 | MAPKAPK5 (0.69) | MAPKAPK5ERN1FYNMAPK1FLT3 | |
| SCHEMBL1477008 | 0.81 | MAPKAPK5 (0.72) | MAPKAPK5FYN | |
| SCHEMBL274887 | 0.79 | MAPKAPK5 (0.40) | MAPKAPK5ERN1FYNMKNK1TTK | |
| SCHEMBL1477728 | 0.75 | MAPKAPK5 (0.55) | MAPKAPK5MKNK1TTKFLT3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131446-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases | GALAPAGOS, N.V. (BE) | 2009-05-21 | — | — | US | claimed |
| US-8138193-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-20 | — | — | US | disclosed |
| US-8133895-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-13 | — | — | US | disclosed |
| US-20100240666-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2010-09-23 | — | — | US | disclosed |
| US-20090131446-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases | GALAPAGOS, N.V. (BE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131446-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases | NOD1, TNF, NOD2 | MAPKAPK5 1247/4885ERN1 2271/4885FYN 4245/4885 |
| US-20100240666-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | RRP15, RARS2, RO60 | MAPKAPK5 1958/4885ERN1 1956/4885FYN 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.